Development and validation of a highly sensitive and robust LC-MS/MS with electrospray ionization method for quantification of rosuvastatin in small volume human plasma samples and its application to a clinical study

Arzneimittel-Forschung/Drug Research

Volumn 57, Issue 11, 2007, Pages 705-711

  Kallem, Raja Reddy ^a   Karthik, Arumugam ^a   Chakradhar, Lagishetty ^a   Mullangi, Ramesh ^a   Srinivas, Nuggehally R ^a  

^a DR REDDY'S LABORATORIES LTD   (India)

Author keywords

CAS 287714 41 4; HMG CoA reductase enzyme inhibitors; Rosuvastatin, human plasma, LC MS MS, method validation, pharmacokinetics

Indexed keywords

ACETONITRILE; ATORVASTATIN; ROSUVASTATIN;

AREA UNDER THE CURVE; ARTICLE; CLINICAL STUDY; CONTROLLED STUDY; DRUG DETERMINATION; DRUG SENSITIVITY; DRUG SPECIFICITY; DRUG STRUCTURE; ELECTROSPRAY; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; NORMAL HUMAN; QUANTITATIVE ANALYSIS; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS;

EID: 36949004947     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296671     Document Type: Article

References (18)

1. Brown WV, Bays HE, Hassman DR, McKenney J, Chitra R, Hutchinson H, et al. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: A randomized, double-blind, 52-week trial. Am Heart J. 2002;144(6):1036-1043.
2. Olsson AG, McTaggart F, Raza A. Rosuvastatin: A highly effective new HMG-Co-A reductase inhibitor. Cardiovas Drug Rev. 2002;20(4):303-328.
3. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses. Am J Cardiol. 2003;92:152-160
4. Olsson AG, Pears J, McKellar J, Mizan J, Raza A. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol. 2001;88:504-508.
5. Davidson M, Ma P, Stein EA, Gotto AM, Raza A, Chitra R, et al. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol. 2002;89(3):268-275.
6. Paoletti R, Fahmy M, Mahla G, Mizan J, Southworth H. Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: a randomized, double-blind study. J Cardiovasc Risk. 2001;8(6):383-390.
7. Olsson A, Southworth H, Wilpshaar JW. Long-term efficacy and safety of rosuvastatin: results of a 52-week comparator-controlled trial versus atorvastatin. Eur Heart J. 2001;22(Suppl):253.
8. Brown WV, Chitra RR, Zedler BK, Bays HE, Hassman HA. Long-term efficacy and safety of rosuvastatin: results of a 52-week comparator-controlled trial versus pravastatin and simvastatin. Eur Heart J. 2001;22(Suppl):270.
9. Hull CK, Pennman AD, Smith CK, Martin PD. Quantification of rosuvastatin in human plasma by automated solid phase extraction using tandem mass spectrometric detection. J Chromatogr B. 2002;772:219-228.
10. Trivedi RK, Kallem RR, Mullangi R, Srinivas NR. Simultaneous determination of rosuvastatin and fenofibric acid in human plasma by LC-MS/MS with electrospray ionization: Assay development, validation and application to a clinical study. J Pharm Biomed Anal. 2005;39:661-669.
11. Oudfoff KA, Sangster T, Thomas E, Wilson ID. Application of microbore HPLC in combination with tandem mass spectrometer for the quantification of rosuvastatin in human plasma. J Chromatogr B 2006;832:191-196.
12. Xu DH, Ruan ZR, Zhou Q, Yuan H, Jiang B. Quantitative determination of rosuvastatin in human plasma by liquid chromatography with electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom. 2006;20(16):2369-2375.
13. Kumar TR, Shitut NR, Kumar PK, Vinu MC, Kumar VV, Mullangi R, et al. Determination of rosuvastatin in rat plasma by HPLC: validation and its application to pharmacokinetic studies. Biomed Chromatogr. 2006;20(9):881-887.
14. Vittal S, Shitut NR, Kumar TR, Vinu MC, Mullangi R, Srinivas NR. Simultaneous quantitation of rosuvastatin and gemfibrozil in human plasma by high-performance liquid chromatography and its application to a pharmacokinetic study. Biomed Chromatogr. 2006;20(11):1252-1259.
15. Guidance for industry: Bioanalytical Method Validation, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CV); 2001. http://www/fda.gov/cder/guidance/index.htm
16. Shah VP, Midha KK, Findlay JH, Hill HM, Hulse JD, Mcgliveray IJ, et al. Bioanalytical method validation-a revisit with a decade of progress. Pharm Res. 2000;17(12):1551-1557.
17. United States Pharmacopoeia, United States Pharmacopoeial Convention: Rockville, MD, USA; 1995.
18. Hubert Ph, Chiap P, Crommen J, Boulanger B, Chapuzet E, Mercier N, et al. The SFSTP guide on the validation of chromatographic methods for drug bioanalysis Washington conférence to the laboratory. Anal Chim Acta. 1999;391(2):135-148.